Socioeconomic status (SES) has led to treatment and survival disparities; however, limited data exist for non-small cell lung cancer (NSCLC). This study investigates the impact of SES on NSCLC diagnostic imaging, treatment, and overall survival (OS), and describes temporal disparity trends. The Ontario Cancer Registry was used to identify NSCLC patients diagnosed between 2007 and 2016. Through linkage to administrative datasets, patients' demographics, imaging, treatment, and survival were obtained. Based on median household neighborhood income, the Ontario population was divided into five income quintiles (Q1-Q5; Q1 = lowest income). Multivariable regressions assessed SES association with OS, imaging, treatment receipt, and treatment delay, and their interaction with year of diagnosis to understand temporal trends. Endpoints were adjusted for demographics, stage and comorbidities, along with treatments and imaging for OS. A total of 50 542 patients were identified. Higher SES patients (Q5 vs. Q1) showed improved 5-year OS (hazard ratio, 0.89; 95% confidence interval [CI], 0.87-0.92; P < .0001) and underwent greater magnetic resonance imaging head (stages IA-IV; odds ratio [OR], 1.24; 95% CI, 1.16-1.32; P < .0001), lung resection (IA-IIIA; OR, 1.58; 95% CI, 1.43-1.74; P < .0001), platinum-based vinorelbine adjuvant chemotherapy (IB-IIIA; OR, 1.63; 95% CI, 1.39-1.92; P < .0001), palliative radiation (IV; OR, 1.14; 95% CI, 1.05-1.25; P = .023), and intravenous chemotherapy (IV; OR, 1.45; 95% CI, 1.32-1.60; P < .0001). Lower SES patients underwent greater thoracic radiation (IA-IIIB; OR, 0.86; 95% CI, 0.79-0.94; P = .0003). Across 2007-2016, socioeconomic disparities remain largely unchanged (interaction P > .05) despite widening income inequality.

中文翻译：

---

2007-2016 年非小细胞肺癌诊断成像、治疗和生存的社会经济差异趋势。

社会经济地位 (SES) 导致治疗和生存差异；然而，非小细胞肺癌 (NSCLC) 的数据有限。本研究调查了 SES 对 NSCLC 诊断成像、治疗和总生存期 (OS) 的影响，并描述了时间差异趋势。安大略癌症登记处用于识别 2007 年至 2016 年间诊断出的 NSCLC 患者。通过与管理数据集的链接，获得患者的人口统计学、影像学、治疗和存活率。根据家庭邻里收入中位数，安大略人口被分为五个收入五分位数（Q1-Q5；Q1 = 最低收入）。多变量回归评估了 SES 与 OS、影像学、接受治疗和治疗延迟的关联，以及它们与诊断年份的相互作用，以了解时间趋势。终点根据人口统计学、分期和合并症以及 OS 的治疗和成像进行了调整。共确定了 50 542 名患者。SES 较高的患者（Q5 与 Q1）显示出改善的 5 年 OS（风险比，0.89；95% 置信区间 [CI]，0.87-0.92；P < .0001）并接受了更大的磁共振成像头（阶段 IA-IV ；优势比 [OR]，1.24；95% CI，1.16-1.32；P < .0001），肺切除术（IA-IIIA；OR，1.58；95% CI，1.43-1.74；P < .0001），铂-基于长春瑞滨的辅助化疗（IB-IIIA；OR，1.63；95% CI，1.39-1.92；P < .0001），姑息性放疗（IV；OR，1.14；95% CI，1.05-1.25；P = .023），和静脉化疗（IV；OR，1.45；95% CI，1.32-1.60；P < .0001）。较低 SES 患者接受较大的胸部放疗（IA-IIIB；OR，0.86；95% CI，0.79-0.94；P = .0003）。2007-2016 年间，